Joel Greenblatt's ACAD Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 43,167 shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $921,184, representing 0.00% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 34,240 shares. Largest reduction occurred in Q1 2025, reducing 35,892 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2016 | +25,682 | New Buy | 25,682 | $28.85 |
| Q1 2017 | -25,682 | Sold Out | 25,682 | $0.00 |
| Q3 2017 | +38,843 | New Buy | 38,843 | $37.66 |
| Q4 2017 | -38,843 | Sold Out | 38,843 | $0.00 |
| Q3 2019 | +28,022 | New Buy | 28,022 | $36.01 |
| Q4 2019 | -12,364 | Reduce 44.12% | 15,658 | $42.79 |
| Q1 2020 | -8,683 | Reduce 55.45% | 6,975 | $42.29 |
| Q2 2020 | -6,975 | Sold Out | 6,975 | $0.00 |
| Q2 2024 | +30,597 | New Buy | 30,597 | $16.25 |
| Q3 2024 | +5,129 | Add 16.76% | 35,726 | $15.38 |
| Q4 2024 | +34,240 | Add 95.84% | 69,966 | $18.35 |
| Q1 2025 | -35,892 | Reduce 51.30% | 34,074 | $16.61 |
| Q2 2025 | -16,467 | Reduce 48.33% | 17,607 | $21.57 |
| Q3 2025 | +25,560 | Add 145.17% | 43,167 | $21.34 |
Joel Greenblatt's ACADIA Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q4 2016, acquiring 25,682 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held ACADIA Pharmaceuticals Inc. (ACAD) for 36 quarters since Q4 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q3 2017, adding 38,843 shares worth $1.46 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 43,167 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $921,184. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 69,966 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.